TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03528603

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oleocanthal-Rich Extra Virgin Olive Oil
Description: Extra Virgin Olive Oil that contains a high level of the phenolic oleocanthal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oleocanthal-Rich Extra Virgin Olive Oil
Description: Extra Virgin Olive Oil that contains a high level of the phenolic oleocanthal

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oleocanthal-low Extra Virgin Olive Oil
Description: Extra Virgin Olive Oil that contains a low level of the phenolic oleocanthal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oleocanthal-low Extra Virgin Olive Oil
Description: Extra Virgin Olive Oil that contains a low level of the phenolic oleocanthal
Study: NCT02219659

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sedation Protocol with Daily Interruption
Description: Continuous infusion of fentanyl and midazolam is started and titrated to target pain and RASS score: Fentanyl started at 25 mcg/hr titrated by 25 mcg/hr every 30 minutes to goal pain score; Midazolam started at 1 mg/hr titrated by 1 mg/hr every hour to goal RASS score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning both infusions are stopped and when the patient is awake and met the SBT safety screen, 120-min CPAP trial is performed. If the patient meets the CPAP passing criteria, arterial blood gas (ABG) is done and the patient is placed back to the previous ventilator setting. ABG result is notified to the physician for determination for extubation. If the patient does not pass the CPAP trial it is repeated next morning.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sedation Protocol Without Daily Interruption
Description: Continuous infusion of fentanyl and midazolam is started and titrated to target pain and RASS score: Fentanyl started at 25 mcg/hr titrated by 25 mcg/hr every 30 minutes to goal pain score; Midazolam started at 1 mg/hr titrated by 1 mg/hr every hour to goal RASS score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning when the patient's RASS score is 0 to -2 and the patient passes the SBT safety screen, 120-min CPAP trial is performed. If the patient meets the CPAP passing criteria, arterial blood gas (ABG) is done and the patient is placed back to the previous ventilator setting. ABG result is notified to the physician for determination for extubation. If the patient does not pass the CPAP trial it is repeated next morning.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Push First
Description: Fentanyl 25 mcg intravenous push (IVP) every 5 min up to 4 doses hourly as needed to target pain score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning when patient's RASS is 0 to -2 and passes the SBT safety screen, 120-min CPAP trial is performed. If patient meets CPAP passing criteria, the physician will be notified for determination of extubation. If patient does not pass, it is repeated next morning. If target RASS is not achieved with fentanyl IV push alone, study team is notified and fentanyl infusion at 50 mcg/hr titrated by 25 mcg/hr every 30 min to target pain score (max 6 hrs). If target RASS score is not achieved with the fentanyl IV, propofol infusion is started at 5 mcg/kg/hr titrated by 5 mcg/kg/hr every 15 min to target RASS score (max 6 hrs).
Study: NCT05144659

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double faced transverse preputial onlay island flap
Description: A well-established one-stage repair of penile hypospadias called Double faced transverse preputial onlay island flap
Study: NCT04178252

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: headset
Description: investigators will add headset to standard treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: headset
Description: investigators will add headset to standard treatment
Study: NCT05144659

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transverse inner preputial onlay island flap
Description: A second well-established one-stage repair of penile hypospadias called Transverse inner preputial onlay island flap
Study: NCT02265354

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collective-Intelligence computer tailored health communication

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rule-based computer tailored health communication
Study: NCT04178252

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard drug
Description: investigators will use 10 mg metoclopramide in 150 ml saline given IV over 10 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard drug
Description: investigators will use 10 mg metoclopramide in 150 ml saline given IV over 10 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard drug
Description: investigators will use 10 mg metoclopramide in 150 ml saline given IV over 10 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard drug
Description: investigators will use 10 mg metoclopramide in 150 ml saline given IV over 10 minutes
Study: NCT04188418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate Buccal Tablet
Description: Given transmucosally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Performance Testing
Description: Complete shuttle walk test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Performance Testing
Description: Complete shuttle walk test

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Performance Testing
Description: Complete shuttle walk test

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02845479

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrative Care
Description: Standardized supplemental/natural health product, physical, nutritional and mental/emotional recommendations based on the phases of standard care (neo-adjuvant, perioperative, adjuvant and long-term maintenance).
Study: NCT03842969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7234292 (RG6042)
Description: Intrathecal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7234292 (RG6042)
Description: Intrathecal injection
Study: NCT04433689

Intervention type: DEVICE
Intervention: Non-Contact measurement of corneal properties
Description: Corneal Properties will be measurement with the non-contact Corvis ST Air-Puff Tonometer by Oculus Inc.
Study: NCT01159171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 5 mg/kg intravenously every 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: 1000 mg/m2 orally b.i.d. , Days 1 - 14 of every 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 40 mg/m2 iv weekly
Study: NCT00121524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Epinephrine 1 mg is given iv. every 3 min during CPR

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravenous needle
Description: An intravenous needle in placed as soon as possible during CPR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: Atropine 3 mg iv in initial systole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone
Description: amiodarone 300 mg iv after repeated failed defibrillation attempts
Study: NCT03193723

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US guided five step field block
Description: Ultrasound will guide needle insertion in the following layers (except intradermic injection):~* Subdermic infiltration. Approximately 8 milliliters~* Intradermic injection (making of the skin wheal). of approximately 6 milliliters.~* Deep subcutaneous injection. 8 milliliters of the mixture will be injected deep into the subcutaneous adipose~* Subfascial infiltration. Approximately eight milliliters of the anesthetic mixture will be injected immediately underneath the aponeurosis of the external oblique.~* Pubic tubercle and hernia sac injection. Occasionally, infiltration of ten milliliters of the mixture at the level of the pubic tubercle, around the neck and inside the indirect hernia sac

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia
Description: Spinal anesthesia will be administered in sitting position, with 25 gauge Quincke spinal needle in L3-L4 intervertebral space, under all aseptic precautions and local infiltration, with 3.0 ml of 0.5% bupivacaine (heavy) after ensuring free, clear and adequate flow of cerebrospinal fluid. After giving spinal anesthesia, patient will be made to lie supine.
Study: NCT05037448

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Me & My Wishes
Description: Me \& My Wishes videos communicate residents' preferences via personalized video recorded conversations. Me \& My Wishes are videos of nursing home residents talking about their preferences for care, and include four sections: About Me, Preferences for Today, Preferences for Medical Intervention and End of Life, and Afterthoughts.
Study: NCT04484896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gain-framed SMS message
Description: Emergency recruitment cell phone short messages that emphasizing donating blood can save patients' lives were sent to donors in this group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Loss-framed SMS message
Description: Emergency recruitment cell phone short messages emphasizing that donating blood can prevent patients from death were sent to donors in this group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information SMS message
Description: Emergency recruitment cell phone short messages that only mentioning the low Rh-negative blood stockpile were sent to donors in this group.
Study: NCT01416103

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Alcohol treatment paralleling welfare-to-work participation: The participants are referred to the municipalities' outpatient alcohol treatment programmes and at the same time referred to an ordinary welfare-to-work programme.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: The participants will as usual be referred to the welfare-to-work schemes deemed most appropriate by the caseworker. The intervention is no different than what the municipality would have offered if the participant was not part of the study.
Study: NCT02502227

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: Mindfulness training practices aim to foster attention and acceptance toward one's present moment experience. Mindfulness consists of two components-- (1) deploying attention to monitor one's moment-to-moment experience, and (2) fostering an attitude of acceptance toward one's moment-to-moment experience

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: Mindfulness training practices aim to foster attention and acceptance toward one's present moment experience. Mindfulness consists of two components-- (1) deploying attention to monitor one's moment-to-moment experience, and (2) fostering an attitude of acceptance toward one's moment-to-moment experience
Study: NCT01704729

Intervention type: PROCEDURE
Group type: OTHER
Intervention: group1
Description: Non-cycloplegic self-refraction +conventional glasses

Intervention type: PROCEDURE
Group type: OTHER
Intervention: group2
Description: Cycloplegic subjective refraction by experienced optometrist +conventional glasses

Intervention type: PROCEDURE
Group type: OTHER
Intervention: group3
Description: Cycloplegic subjective refraction by Rural Refractionist Program + conventional glasses

Intervention type: PROCEDURE
Group type: OTHER
Intervention: group4
Description: Cycloplegic subjective refraction by an experienced optometrist +ready-made glasses
Study: NCT02396771

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine Massage
Description: The massage will be performed as follows: palpating the uterine fundus, manually stimulating the fundus and the whole body of the uterus using fingers and palms steadily and repetitively.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine Compression
Description: The sustained uterine compression will be performed as follows: placing one hand in the vagina and pushing against the body of the uterus while the other hand compresses the fundus from above through the abdominal wall.
Study: NCT03626636

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risuteganib
Description: Subjects injected intravitreally with 1.0mg of Luminate®

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham
Description: Sham injection
Study: NCT00395291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0677
Description: The dosage of the drug is 25mg, subjects will take one pill a day for about 30 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0677
Description: The dosage of the drug is 25mg, subjects will take one pill a day for about 30 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT03429673

Intervention type: PROCEDURE
Intervention: Surgeries
Description: Lobectomy or segment/wedge dissection
Study: NCT01214304

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Essential Lavender Oil
Description: Aromatherapy with essential lavender oil will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure (patient dressed and ready to leave the room). The essential lavender oil and will be administered by fan diffuser.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lavender Scent
Description: Aromatherapy with a fake lavender scent (placebo) will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure (patient dressed and ready to leave the room). The fake lavender scent will be administered by fan diffuser.
Study: NCT00420004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: 3-mg and 6-mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 10-mg capsules
Study: NCT00309140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 500 milligrams (mg), oral, daily, six 42-day cycle and subsequent cycles or until participants met study discontinuation criteria of progressive disease or unacceptable toxicity
Study: NCT01223885

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Camel's milk
Description: Patients with proved cow's milk allergy who have negative prick skin tests to came's milk will be administered gradually increased doses of pasteurized camel's milk at 30 minute intervals
Study: NCT05901363

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiopancreatography plus laparoscopic cholecystectomy
Description: laparoscopic removal of gallbladder and endoscopic extraction of common bile duct stones

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: aparoscopic common bile duct exploration and laparoscopic cholecystectomy
Description: laparoscopic removal of gallbladder and laparoscopic extraction of common bile duct stones
Study: NCT01381003

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: pCCLchimGp91s lentiviral vector transduced CD34+ cells infusion
Description: pCCLchimGp91s lentiviral vector transduced CD34+ cells will be infused in a volume of 50-100 mls intravenously over 30-45 minutes
Study: NCT00785421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enoxaparin
Description: Patients receive GFFC +/- LMWH (gemcitabine 1 g/m2 (30 min), cisplatin 30 mg/m2 (90 min), 5-fluorouracil 750 mg/m2 (24 h), folinic acid 200 mg/m2 (30 min), d1, 8; q3w +/- Enoxaparin 1mg/kg daily s.c.). Pts with KPS \< 80 % and increased creatinin plasma levels (\>1.3 mg/dl) receive the current standard therapy (gemcitabine 1 g/m2 (30 min), d1, 8, 15; q4w) +/- LMWM +/- Enoxaparin 1mg/kg daily s.c. After 12 weeks of initial chemotherapy all patients who have not progressed received the standard therapy (gemcitabine mono) +/- Enoxaparin 40mg/d s.c.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy with LMWH - enoxaparin
Description: 1-12 weeks: enoxaparin 1g/m², s.c. 12-PD or event: enoxaparin 0,4g s.c.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: only chemotherapy
Description: observation, no treatment with LMWH
Study: NCT02460913

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture session of 20 to 30 minutes. Treatment protocols were determined through review of major clinical manuals and textbooks, literature review, and a panel of specialist acupuncturists from Chinese medicine backgrounds.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine titration
Description: Patients in this group received IV titrated morphine. Morphine was prepared onsite and diluted in a manner to obtain a dose of 1mg in each ml of normal saline. The initial dose was 0.1 mg per kg and a titration dose of 0.05 mg per Kg was repeated every 5 minutes until reaching objective. The maximum allowed dose was 1.5 mg/kg.
Study: NCT03638908

Intervention type: DRUG
Group type: OTHER
Intervention: Fluoxetine
Study: NCT00100230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docosahexaenoic acid OR corn/soy oil placebo
Description: daily intake of DHA based on body weight or corn/soy oil placebo(oil not containing DHA; 4 year trial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: docosahexaenoic acid OR corn/soy oil placebo
Description: daily intake of DHA based on body weight or corn/soy oil placebo(oil not containing DHA; 4 year trial
Study: NCT02269176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose of telmisartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of telmisartan
Study: NCT02514447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Study: NCT02635555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: 100 mcg of phenylephrine or 5 mg ephedrine given as deemed necessary for treating episodes of hypotension.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: 100 mcg of phenylephrine or 5 mg ephedrine given as deemed necessary for treating episodes of hypotension.
Study: NCT03273192

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: A single 40-mg dose of Adalimumab is administered subcutaneously to all the subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: A single 40-mg dose of Adalimumab is administered subcutaneously to all the subjects.
Study: NCT04273217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-1
Description: Single dose, administered by IV infusion (volume: 250 mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-1
Description: Single dose, administered by IV infusion (volume: 250 mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-1
Description: Single dose, administered by IV infusion (volume: 250 mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-1
Description: Single dose, administered by IV infusion (volume: 250 mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-1
Description: Single dose, administered by IV infusion (volume: 250 mL)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sterile saline. Administered by IV infusion (volume: 250 mL)
Study: NCT05308745

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Yakult®
Description: Fermented milk drink containing over 6.5×10\^9 CFUs of L. casei Shirota/65 ml

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taste, appearance, component, and number of calories are the same as Yakult®, non-fermented milk product
Study: NCT01843751

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buprenorphine/naloxone
Description: Buprenorphine/naloxone (Suboxone) is considered a well-investigated, highly effective medication-assisted treatment for opiate dependence, but it may only be supervised through the few specialist treatment facilities in the state, or by physicians who have historically been less likely to offer this service. The effectiveness of community physician treatment supervision has not been tested for those in the criminal justice system.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine/naloxone
Description: Buprenorphine/naloxone (Suboxone) is considered a well-investigated, highly effective medication-assisted treatment for opiate dependence, but it may only be supervised through the few specialist treatment facilities in the state, or by physicians who have historically been less likely to offer this service. The effectiveness of community physician treatment supervision has not been tested for those in the criminal justice system.
Study: NCT00527007

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External cooling
Description: External cooling
Study: NCT02354079

Intervention type: GENETIC
Group type: OTHER
Intervention: hypobetalipoproteinemia genetic and genotypic screening